Navigation Links
ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
Date:2/7/2008

SAN DIEGO, Feb. 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), announced today that complete pharmacokinetic data from the Company's marketing-enabling bioequivalence clinical study of ANX-530 (vinorelbine emulsion) has been accepted for presentation at the 2008 American Association for Cancer Research (AACR) Annual Meeting, which takes place April 12 - 16, 2008 in San Diego, CA.

The poster presentation entitled "Pharmacokinetic equivalence observed between an emulsion formulation of vinorelbine (ANX-530) and vinorelbine solution in a clinical study of patients with advanced cancer," is scheduled to be presented on April 13, 2008.

ADVENTRX recently completed a marketing-enabling bioequivalence clinical study of ANX-530. The primary endpoint in the study was met, with pharmacokinetic equivalence observed between ANX-530 and the reference drug Navelbine(R). Furthermore, ANX-530 demonstrated a statistically significant reduction in injection site reactions when compared to Navelbine. Presentation of complete safety results including injection site reactions, have been submitted for presentation at an upcoming oncology conference. ADVENTRX intends to submit to the U.S. Food and Drug Administration (FDA) a Section 505(b)(2) New Drug Application (NDA) for ANX-530 in the fourth quarter of 2008.

About ANX-530 (vinorelbine emulsion)

ANX-530 is designed to reduce the incidence and severity of injection site reactions from intravenous delivery of vinorelbine tartrate. Vinorelbine tartrate works by disrupting microtubule formation and is a member of the vinca alkaloid class of antineoplastic agents. Vinorelbine is indicated as a single agent or in combination with cisplatin for treatment of advanced
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Announces Consolidation of Clinical and Management Positions
2. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
3. ADVENTRX Appoints Vice President of Commercialization
4. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
5. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
8. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
9. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
10. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ) ... ) has submitted a pre-market approval application to the ... of Medtronic,s SynchroMed ® II implantable drug infusion ... United Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously ...
(Date:12/24/2014)... Missouri (PRWEB) December 23, 2014 GMO corn ... company, Syngenta, are in the process of being consolidated in ... is In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... of Kansas. , Management of the Syngenta GMO corn multidistrict ...
(Date:12/24/2014)... 2014 The report provides basic ... classification, application and industry overview. This report also ... structure. Production is separated by regions, technology and ... equipment, downstream client survey, marketing channels, industry development ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... LASIK Surgeons directory service and information resource for ... Trusted LASIK Surgeons directory apart is a unique ... surgeon who are among the best in the ... LASIK Surgeon Dr. Parag A. Majmudar, are screened ...
... line in the United ... States and Canada, ... into a partnership that will allow Roche to market,the first line ... the RAMP(R) 200 (Rapid Analyte Measurement Platform), is,based on RAMP technology ...
... Medical,Technologies, Inc. (Nasdaq: VNUS ), a leading provider ... reflux disease, today,announced its plans to present at the ... held August 5-6, 2008, at the Millennium,Broadway Hotel in ... for 10:00 a.m. ET on,Wednesday, August 6, and will ...
Cached Biology Technology:Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons 2Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons 3Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons 4Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons 5Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons 6Roche and Response Biomedical Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests 2Roche and Response Biomedical Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests 3
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has ... - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally different ... the first time a fingerprint sensor in its product. ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used for the ... facial feature of a person such as nose, jaw ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Northwest is the focus of two federal grants totaling ... They will work together on a pair of multi-site ... and property from wildfires in the face of a ... the UO,s Center for Ecology and Evolutionary Biology, will ...
... of the element boron in a new generation of drugs ... Boron has to date far been one of biology,s best ... and investment from the pharmaceutical industry in the quest for ... limitations and side effects of current products. Europe,s ...
... Conventional wisdom has been that respiratory syncytial virus (RSV) ... comes and goes in children without any long lasting impact. ... Southwestern Medical Center researchers, however, suggests that RSV may hide ... to cause recurrent wheezing and chronic airway disease. ...
Cached Biology News:Northwest climate change is target of $3.2M in grants to University of Oregon 2Northwest climate change is target of $3.2M in grants to University of Oregon 3Northwest climate change is target of $3.2M in grants to University of Oregon 4European researchers harness unique properties of boron to develop new drugs and diagnostics 2European researchers harness unique properties of boron to develop new drugs and diagnostics 3RSV may hide in the lungs, lead to asthma, UT Southwestern researchers report 2RSV may hide in the lungs, lead to asthma, UT Southwestern researchers report 3
...
... SELECT Stabilizer is an aqueous solution that ... non-toxic stabilizing chemicals in a saline solution, ... combination of 0.02% methylisothiazolone and 0.02% bromonitrodioxane ... is a diluent and stabilizer for biologically ...
... The lyophilization stabilizer is designed to ... and for long-term storage. There ... ingredients. It is a convenient ... 7.2, and is superior to other ...
... CERTOMAT IS, a true benchtop incubator-shaker, has the ... Having a footprint of 540 x 680 mm ... incubation chamber (370 x 505 x 510mm). Available ... CERTOMAT IS is ideal for shaking applications requiring ...
Biology Products: